New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 3, 2013
08:40 EDTOMEDOncoMed reports Q2 EPS ($8.83), may not compare to consensus (2c)
Reports Q2 revenue $2.9M, may not compare to consensus $8.31M. The decrease in revenue vs. $7.5M in 2Q12 was mainly a result of timing of a $5M milestone payment that was achieved in the 2Q12, offset by $400K in collaboration revenue recognized in the 2Q13 related to the amortization of a payment from Bayer received in August 2012.
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
10:59 EDTOMEDOncoMed management to meet with Piper Jaffray
Meetings to be held in San Francisco October 7-8 hosted by Piper Jaffray.
September 30, 2014
12:12 EDTOMEDOncoMed cancer pipeline expanded with new candidate, says Piper Jaffray
Subscribe for More Information
08:37 EDTOMEDOncoMed announces advancement small molecule Wnt pathway inhibitor
Subscribe for More Information
September 29, 2014
07:17 EDTOMEDOncoMed data supports phase 2 ALPINE study of tarextumab
Subscribe for More Information
September 28, 2014
14:23 EDTOMEDOncoMed demcizumab trials show 'encouraging' safety and anti-tumor activity
OncoMed Pharmaceuticals presented safety and efficacy data from two Phase 1b clinical trials of demcizumab in pancreatic cancer and non-small cell lung cancer, NSCLC, at the European Society for Medical Oncology 2014 Congress in Madrid, Spain. Results from the Phase 1b studies demonstrate that demcizumab, in combination with standard-of-care chemotherapy, is well tolerated, especially in patients where the company's risk mitigation, monitoring and truncated dosing strategies have been employed. Encouraging tumor response rates were presented at ESMO from a study of demcizumab with gemcitabine or gemcitabine plus Abraxane in patients with first-line pancreatic cancer, and from the study of demcizumab plus pemetrexed and carboplatin for the first-line treatment of Stage III/IV NSCLC. OncoMed's Phase 1b studies identified the demcizumab dosing schedules for the company's planned randomized Phase 2 proof-of-concept trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use